Effect of antibiotic guidelines on outcomes of hospitalized patients with nursing home-acquired pneumonia

J Am Geriatr Soc. 2009 Jun;57(6):1030-5. doi: 10.1111/j.1532-5415.2009.02279.x. Epub 2009 Apr 30.

Abstract

Objectives: To compare the 2003 community-acquired pneumonia (CAP) guideline and the 2005 healthcare-associated pneumonia (HCAP) guideline on time to clinical stability, length of hospital stay, and mortality in nursing home patients hospitalized for pneumonia.

Design: Retrospective study.

Setting: Three tertiary-care hospitals.

Participants: Three hundred thirty-four nursing home patients.

Measurements: Patients were classified according to the antibiotic regimens they received based on the 2003 CAP guideline or the 2005 HCAP guideline. Time to clinical stability, time to switch therapy, and mortality were evaluated in an intention-to-treat analysis. A multivariate survival model using propensity analysis was used to adjust for heterogeneity between the two groups.

Results: Of the 334 patients, 258 (77%) were treated according to the 2003 HCAP guideline. Time to clinical stability did not differ between those treated according to the 2003 CAP or the 2005 HCAP guidelines. Only the Pneumonia Severity Index (P=.006) and multilobar involvement (P=.005) were significantly associated with delay in achieving clinical stability. Adjusted in-hospital and 30-day mortality were comparable in both cohorts (odds ratio (OR)=0.87, 95% confidence interval (CI)=0.49-1.34, and OR=0.79, 95% CI=0.42-1.31, respectively), although time to switch therapy and length of stay were longer for those treated according to the 2005 HCAP guideline.

Conclusion: In hospitalized nursing home patients with pneumonia, treatment with an antibiotic regimen according to the 2003 CAP guideline achieved comparable time to clinical stability and in-hospital and 30-day mortality with a regimen based on the 2005 HCAP guideline.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Anti-Bacterial Agents / administration & dosage*
  • Comorbidity
  • Cross Infection / drug therapy*
  • Female
  • Humans
  • Length of Stay
  • Male
  • Nursing Homes*
  • Pneumonia / drug therapy*
  • Pneumonia / mortality
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents